Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Onvansertib fumarate by Cardiff Oncology for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Onvansertib fumarate is under clinical development by Cardiff Oncology and currently in Phase II for Relapsed Acute Myeloid Leukemia. According...
Onvansertib fumarate by Cardiff Oncology for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Onvansertib fumarate is under clinical development by Cardiff Oncology and currently in Phase II for Refractory Acute Myeloid Leukemia. According...
Onvansertib fumarate by Cardiff Oncology for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Onvansertib fumarate is under clinical development by Cardiff Oncology and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...
Onvansertib fumarate by Cardiff Oncology for Small-Cell Lung Cancer: Likelihood of Approval
Onvansertib fumarate is under clinical development by Cardiff Oncology and currently in Phase II for Small-Cell Lung Cancer. According to...
Onvansertib fumarate by Cardiff Oncology for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Onvansertib fumarate is under clinical development by Cardiff Oncology and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute...
Onvansertib fumarate by Cardiff Oncology for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Onvansertib fumarate is under clinical development by Cardiff Oncology and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...
Onvansertib fumarate by Cardiff Oncology for Metastatic Colorectal Cancer: Likelihood of Approval
Onvansertib fumarate is under clinical development by Cardiff Oncology and currently in Phase II for Metastatic Colorectal Cancer. According to...